An honest review of Jeuveau, the neuromodulator manufactured by Evolus that's purported to kick in faster and last longer than Botox.

Jeuveau is the newest version of botulinum toxin A, the same active ingredient in the original Botox Cosmetic. Here's what you need to know.

Jeuveau’s formulation is very similar to Botox, but it’s specifically marketed for cosmetic use, which makes it a great ...

Evolus’ injectable neurotoxin, Jeuveau, which was approved in 2019, knows exactly what it is. It’s an aesthetic product, and that’s all it wants to be.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, unveils fresh, new branding for its flagship neurotoxin product, Jeuveau ...

This laidback approach to broadening interest and access to neurotoxins appears to be working: Jeuveau revenue grew to $148.9 million in 2022, marking a 49% increase over 2021. Yet there is still room ...

Evolus’ Jeuveau (DWP-450) (prabotulinumtoxinA) will likely prove to be a strong competitor to Allergan’s Botox (botulinum toxin type A) for severe glabellar (frown) lines, with an analyst ...

JEUVEAU can cause other serious side effects including: allergic reactions such as itching, rash, red itchy welts, wheezing, trouble breathing, asthma symptoms, or dizziness or feeling faint.

Botched Presents: Plastic Surgery Rewind's first host is an international radio and TV personality with loads of fans. Best known for starring in another reality show, Michelle Visage has been a ...

Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox. Skip to main content ...

Evolus, Inc.'s Jeuveau continues to see growth; unaudited full-year 2022 financials showed revenues reaching $148.6 million. Click here for more on EOLS stock.